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Normal cardiac performance reflects the interdependence
between myocardial mechanical function, myocardial oxy-
gen consumption (MVO2), and blood flow. Indeed, physi-
ologic processes directly associated with systolic function
(e.g., wall stress, shortening, heart rate, contractility) are
major determinants of MVO2. Conversely, when myocardial
blood flow is interrupted, there is rapid cessation of MVO2
and systolic function. The linkage between myocardial
blood flow and mechanical function provided by MVO2
reflects primarily the oxidation of substrates for myocardial
energy production. Consequently, because of the central
role of MVO2 in cardiac physiology, the noninvasive quan-
tification of MVO2 is crucially important in both cardiovas-
cular investigation and clinical cardiology.
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Currently, positron emission tomography (PET) using
11C-acetate is the most accurate and commonly used
method of measuring MVO2 noninvasively. Once taken up
by the heart, acetate, a two-carbon chain free fatty acid, is
rapidly converted to acetyl–coenzyme A (CoA). The pri-
mary metabolic fate of acetyl-CoA is metabolism through
the tricarboxylic acid cycle. Because of the tight coupling of
the tricarboxylic acid cycle and oxidative phosphorylation,
the myocardial turnover of 11C-acetate reflects overall flux
in the tricarboxylic acid cycle and, thus, overall oxidative
metabolism or MVO2. When bi-exponential curve fitting is
used to measure the myocardial kinetics of the tracer, the
rate constant k1, which describes the myocardial clearance of
11C activity (in the form of 11CO2), correlates closely and
directly with MVO2 over a wide range of conditions (1–3).
Because of the relative simplicity of curve fitting, it is the
most commonly used method to measure the myocardial
kinetics of 11C-acetate. Indeed, the method has been
simplified further to measure the clearance from the linear
portion of the myocardial time–activity curve (kmono) (3).
The study reported by Stolen et al. (4) in this issue of the
Journal is a prime example of how measurements of MVO2,
when combined with measurements of myocardial blood
flow and mechanical function, can provide unique insights
into the benefits of a specific cardiac therapy. In brief, the
authors assessed the impact of exercise training on MVO2 in
both the right and left ventricles (RV and LV), as well as
myocardial blood flow and mechanical function in the LV,
in patients with nonischemic dilated cardiomyopathy
(DCM) and mild heart failure (HF). MVO2 was measured
by PET with 11C-acetate using the kmono method. Myo-
cardial blood flow was also measured by PET using 15O-
water. Various parameters of LV volume and systolic
function, as well as LV external work, were measured by
echocardiography. Measurements were performed before
and after five months of participation in an exercise training
program and compared with a comparable group of patients
with DCM who did not participate in the exercise program.
This study makes several key observations regarding
exercise training in patients with DCM and mild HF:
1. It confirms the beneficial effects of exercise training on
exercise capacity, exercise duration, and quality of life.
2. It provides further evidence that exercise training im-
proves LV systolic function (ejection fraction and stroke
volume) without an increase in external work (primarily
because of a decrease in heart rate).
3. It provides new evidence that LV MVO2 decreases in
response to training, which, when coupled with a lack of
change in external work, results in an improvement in
LV efficiency.
4. It provides intriguing evidence that exercise training has
salutary effects on RV oxidative metabolism.
Taken in sum, these findings demonstrate that the
salutary effects of exercise training on exercise capacity and
quality of life in patients with DCM are due not only to
peripheral adaptations, such as improved peripheral endo-
thelial function and increased oxidative capacity in skeletal
muscle, but also to an improvement in LV energetics, function,
and efficiency. Although measurements of RV external work
were not obtained, the decline in MVO2 suggests that RV
energy transduction would be improved as well.
Given that the role of MVO2 measurements by PET
11C-acetate is central in these results and that the decline in
MVO2 after exercise training was modest (10%), certain
questions arise. First, are there effects that might confound the
measurements of the myocardial kinetics of 11C-acetate using
the kmono method and thus reduce or obscure the accuracy of
the MVO2 measurements? If so, are there approaches that
could reduce the impact of these effects and, as a consequence,
improve the accuracy of the measurements? Finally, are there
other approaches on the horizon that may make it easier to
obtain or more accurately measure MVO2 or that may provide
additional information leading to a more comprehensive un-
derstanding of myocardial energetics and efficiency?
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Exponential curve fitting of myocardial 11C-acetate is sus-
ceptible to several factors. The curve fitting is sensitive to the
shape of the time–activity curve in the blood. Said another way,
the accuracy of the estimates of MVO2 will be affected by the
rate of delivery of tracer to the heart during the imaging
interval (5,6). With respect to the RV, the shape of the blood
curve reflects the type of tracer injection (intravenous bolus or
infusion) and recirculation of 11C-acetate. In the case of the
LV, the shape of the blood curve primarily reflects the cardiac
output and tracer recirculation. The slower the initial delivery
of 11C-acetate to the myocardium and/or the more recircula-
tion there is, the slower the clearance rates and thus the lower
the estimates of MVO2. It should be noted that the sensitivity
of exponential curve fitting to this effect is more pronounced
when mono-exponential fitting, as opposed to bi-exponential
fitting, is used (6). The impact of this effect in the current study
was probably small, considering that the patients had class I/II
HF and an average LV ejection fraction of 33%. Moreover, the
decline in rest myocardial blood flow with exercise training
provides further evidence that the decline in MVO2 after
exercise training was physiologically significant. A second
potential disadvantage is that curve fitting may be sensitive to
spillover activity from either the blood or the lungs. If signif-
icant, this would lead to an underestimation of the myocardial
clearance of tracer and, again, an underestimation of MVO2.
Although it is not typically a problem in normal hearts,
spillover may become a problem in situations in which recir-
culation of tracer may be significant or in which lung activity is
increased, as may be seen in patients with marked LV dys-
function. The spillover effect may be even more problematic
when curve fitting is performed on the RV, because of the
relative thinness of the RV myocardium. Finally, the curve-
fitting method provides only an estimate of MVO2. To com-
pare kmono values with previously reported values for MVO2,
kmono (in units of per min) is converted to its equivalent value
for MVO2 (usually in mol/g per min), based on the relation-
ship between these two values measured directly in either dogs
or humans. However, this relationship was usually measured
under normal physiologic conditions. It is unknown whether
the relationship between kmono and MVO2 is altered under
abnormal conditions in which marked alterations in the blood
curve could occur.
To circumvent many of the problems associated with
exponential curve fitting, approaches that utilize compart-
mental modeling of the myocardial 11C-acetate kinetics
have been developed. The advantages of compartmental
modeling are that the effects of variability in the blood curve
and spillover from blood (or lung) to the myocardium can be
taken into account. Moreover, depending on the model
used, MVO2 can be estimated directly, as opposed to
converting rate constants estimated by the model to MVO2
using a previously measured relationship. Indeed, measure-
ments of MVO2 have been shown to be more accurate when
the compartmental modeling method is used as opposed to
exponential curve fitting (6). That being said, there are
several disadvantages associated with compartmental mod-
eling of myocardial 11C-acetate kinetics. First, this method
is more complex and time-consuming than exponential
curve fitting. The blood curve must be corrected for 11CO2
so that an accurate measurement of 11C-acetate blood
activity is obtained. Other physical factors, such as under-
estimation of true tissue activity due to partial volume
effects, can significantly degrade the accuracy of the esti-
mates obtained with compartmental modeling and thus
must be accounted for. Finally, because of the number of
parameters being estimated, the need for high-quality im-
ages is greater with compartmental modeling than exponen-
tial curve fitting. Despite these complexities, numerous
groups have used compartmental modeling of myocardial
11C-acetate kinetics to measure MVO2 under a variety of
normal and abnormal cardiac states (7–9).
Because oxygen is the final electron acceptor in all
pathways of aerobic myocardial metabolism, PET with
15O-oyxgen has also been used to measure MVO2. Admin-
istration of 15O-oxygen is generally performed by inhalation
of the gas, which results in marked spillover of radioactivity
from the lungs to the heart (10). Tracer kinetics are further
complicated by the need to account for the conversion of
O15O to 15O-water and blood to myocardial spillover.
Consequently, four different scans have to performed: a
transmission scan to calculate lung volume; a 15O-carbon
monoxide scan to measure blood volume; a scan using a
PET perfusion tracer to quantify myocardial blood flow;
and the 15O-oxygen scan. However, despite these complex-
ities, a compartmental modeling approach has been devised
that quantifies the myocardial oxygen extraction fraction.
Thus, with the knowledge of the arterial oxygen content and
myocardial blood flow, MVO2 can be accurately calculated
(10,11). The major advantage of the approach is that it
provides a measure of myocardial oxygen extraction and
measures MVO2 directly. Its major disadvantage is the need
for a multiple-tracer study and fairly complex compartmen-
tal modeling to obtain the measurements. Despite these
limitations, the 15O-oxygen method has provided unique
insights into the changes in MVO2 that occur in a variety
abnormal cardiac conditions (12,13).
Because of the close coupling between MVO2 and myo-
cardial mechanical function, separate measurements of LV
function, in addition to the PET measurements of MVO2,
are usually required to obtain a more comprehensive under-
standing of myocardial energetics and efficiency. The sepa-
rate measurements of LV function are usually performed
with a different imaging method, such as echocardiography
or cardiac magnetic resonance imaging (cMRI). The disad-
vantage of this dual-imaging approach is that differences in
hemodynamic conditions between the two imaging sessions
may confound the interpretation of the relationship between
MVO2 and function. Moreover, particularly when regional
assessments are being performed, accurate co-registration of
the images is necessary to ensure that MVO2 and mechanical
function are being measured in the same myocardial seg-
ment. It has been proposed that by obtaining electrocardio-
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graphically gated PET data of myocardial 11C-acetate
kinetics, one can simultaneously acquire measurements of
myocardial work and MVO2 and thus measure efficiency
(14). Consequently, the concerns regarding hemodynamic
differences and image co-registration would be allayed.
Although the initial results in normal volunteers look
promising, confirmation of the accuracy of the method,
when compared with more invasive methods and in patients
with abnormal LV function, is lacking.
In the future, cMRI may play a significant role in the
noninvasive measurement of MVO2 by utilizing the blood
oxygen level–dependent, or BOLD, effect (15). The basic
principle underlying the BOLD effect is that oxyhemoglo-
bin contains no unpaired electrons and is diamagnetic. In
contrast, deoxyhemoglobin has unpaired electrons and is
paramagnetic. Because water and proteins are diamagnetic,
inhomogeneity will occur in the local magnetic field sur-
rounding deoxyhemoglobin. Thus, as the fraction of deoxy-
hemoglobin in the blood increases, there will be signal loss
in blood and tissue on T2- and T2*-weighted images. The
major application for measurements of the BOLD effect has
been in functional brain imaging. Compared with the brain,
the myocardium has a greater blood volume (10% vs.
4%). Moreover, at baseline, the myocardium extracts
more oxygen, leading to a lower oxygen saturation in the
coronary sinus blood (30%) than in the venous blood in
the brain (60%). Consequently, the myocardium has a
wider dynamic range of signal change than does the brain.
The feasibility of using BOLD imaging to detect differences
in myocardial blood oxygenation has been demonstrated
using a variety of interventions. For example, there is signal
enhancement in response to dipyridamole: coronary sinus
blood oxygenation increases due to luxuriant perfusion (16).
No change in signal is observed during dobutamine use:
oxygen supply and demand are matched, and thus no
change in coronary sinus blood oxygenation occurs. By
contrast, with ischemia there is signal loss as oxygen
extraction increases (17). With the use of approaches
devised for measuring oxygen extraction in the brain,
measurements of myocardial oxygen extraction will probably
be developed. As is done with the PET with 15O-oxygen
method, with knowledge of the arterial oxygen content and
level of myocardial blood flow, MVO2 can be calculated.
However, before myocardial oxygen extraction and MVO2
can be measured in humans, numerous hurdles must be
overcome. Some of these difficulties include image degra-
dation due to cardiac and respiratory motion, the inherent
low signal-to-noise ratio, and the relatively low sensitivity of
magnetic resonance contrast to myocardial oxygenation that
is seen with commercial 1.5-tesla systems. Finally, accurate
measurements of myocardial oxygen extraction and MVO2
require a priori knowledge of both myocardial blood flow
and volume. Therefore, both myocardial blood flow and
volume need to be quantified independently. If these prob-
lems can be overcome, then measurements of MVO2 can be
obtained nearly simultaneously with measurements of myo-
cardial wall stress, strain, and work, using well-established
cMRI methods. This would offer the advantage of the
measurements being obtained under similar hemodynamic
conditions and would remove the need to apply image
fusion techniques to ensure accurate image co-registration.
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